On the heels of a stock surge that began when RNAi competitor Sirna Therapeutics Inc. received a hefty buyout offer from Merck & Co. Inc., Alnylam Pharmaceuticals Inc. is raising $101 million through the sale of common stock. (BioWorld Today)
In a deal that could result in $1.2 billion in milestone payments - on top of a $35 million up-front payment - EPIX Pharmaceuticals Inc. signed with GlaxoSmithKline plc to discover, develop and market drugs that target four G-protein-coupled receptors. (BioWorld Today)
Halozyme Therapeutics Inc.'s stock surged 59.2 percent Wednesday following news of an Enhanze technology licensing deal with F. Hoffmann-La Roche Ltd. worth up to $612 million plus royalties. (BioWorld Today)
Talks of an additional trial for the parathyroid hormone nasal spray (PTH1-34) to treat osteoporosis led Nastech Pharmaceutical Co. Inc. and Procter & Gamble Pharmaceuticals Inc. to amend their 10-month-old agreement - meaning Nastech will not receive $15 million in milestone payments this year as expected. (BioWorld Today)
A loss of exclusivity, strong competition and a changing market led Pfizer Inc. to cut its U.S. sales force by 20 percent last week, yet analysts say the move should have little impact - if any - on the biotech community. (BioWorld Today)
